Close

Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. PPG


Go back to Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update

Cantor Fitzgerald Downgrades Tonix Pharma (TNXP) to Hold

September 7, 2016 7:27 AM EDT

Cantor Fitzgerald downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold with a price target of $1.00 (from $5.00).

For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.

Shares of Tonix Pharma closed at $0.92 yesterday.

... More